These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33131514)

  • 1. [Programmed Death-1 Inhibitors-induced Bullous Pemphigoid in 21 Cases].
    Li S; He C; Zuo Y; Jin H
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Oct; 42(5):603-609. PubMed ID: 33131514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.
    Sugawara A; Koga H; Abe T; Ishii N; Nakama T
    J Dermatol; 2021 Mar; 48(3):401-404. PubMed ID: 33184934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
    Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
    Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
    Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
    Front Immunol; 2020; 11():588582. PubMed ID: 33708189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
    JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
    Guan S; Zhang L; Zhang J; Song W; Zhong D
    Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.
    Wang J; Hu X; Jiang W; Zhou W; Tang M; Wu C; Liu W; Zuo X
    Front Oncol; 2023; 13():1095694. PubMed ID: 36937423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
    Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
    Front Immunol; 2019; 10():1934. PubMed ID: 31474998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
    Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
    Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.
    Kosche C; Owen JL; Sadowsky LM; Choi JN
    Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
    Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
    Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
    Sun L; Wang C; Wu C; Zhou Y; Wang C
    Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urticarial Lesions in a Pregnant Woman.
    Santos-Alarcón S; Benavente-Villegas C; García-Briz I; Moneva-Léniz M; Sanchis-Sánchez C; Mateu-Puchades A
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):71-72. PubMed ID: 29782306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
    Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
    Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pemphigoid gestationis: a study of 20 cases].
    Mokni M; Fourati M; Karoui I; El Euch D; Cherif F; Ben Tekaya N; Azaiz MI; Haouat S; Boubaker MS; Ben Osman Dhahri A
    Ann Dermatol Venereol; 2004 Nov; 131(11):953-6. PubMed ID: 15602381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X; Sui D; Wang D; Zhang L; Wang R
    Front Immunol; 2021; 12():731774. PubMed ID: 34594337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.